Impact of next-generation sequencing on routine clinical practice and patient inclusion in molecularly targeted clinical trials: a retrospective cohort analysis
Clinical and Translational Oncology · 2025
DOI: 10.1007/s12094-025-04086-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2025. Verfasst von Mathieu Faigner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, CHU de Poitiers, 86000, Poitiers, France. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Neoplasms, Molecular Targeted Therapy, Patient Selection. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: High-throughput sequencing has advanced biomarker identification, enabling more targeted cancer treatment. Various gene panels are used to screen for actionable genomic alterations for clinical practice and trial inclusion. OBJECTIVES: We aimed to determine the proportion of cancer patients with a targetable molecular tumor alteration and their inclusion in related trials using a routine panel, and to compare these proportions with results from a larger panel combined with molecular tumor board (MTB) discussion. DESIGN: We analyzed eligibility and inclusion in targeted therapy trials among all cancer patients treated at Poitiers University Hospital who underwent routine NGS. METHODS: Clinical trials were identified via the French National Cancer Institute (INCa) and ClinicalTrials.gov databases. Inclusion rates were also assessed for patients analyzed with the broader FoundationOne CDx® (FO) panel. RESULTS: Among 1456 patients, 835 targetable mutations were identified: KRAS 43.6%, BRAF 19.0%, and PIK3CA 10.8%. Of 179 patients eligible for a dedicated trial, 19 were enrolled (10.6%), mostly at Poitiers University Hospital (84.2%) and predominantly melanoma patients (11/19). For 78.8% of non-included eligible patients, reasons were undocumented. FO analysis increased actionable alteration detection from 34.0% to 64.0%, with trial inclusion rising from 12.0% to 16.0%. CONCLUSION: Although a substantial fraction of patients harbored actionable alterations, trial inclusion remained low at our center. Improving access requires better physician awareness of available clinical trials to optimize patient enrollment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Department, CHU de Poitiers, 86000, Poitiers, France.
- Université de Poitiers, ProDicET, UR 24144, 86000, Poitiers, France.
- Cancer Biology Department, CHU de Poitiers, 86000, Poitiers, France.
- Gastro-Enterology and Hepatology Department, CHU de Poitiers, 86000, Poitiers, France.
- Medical Oncology Department, CHU de Poitiers, 86000, Poitiers, France. Camille.evrard@chu-poitiers.fr.
- Université de Poitiers, ProDicET, UR 24144, 86000, Poitiers, France. Camille.evrard@chu-poitiers.fr.
Zitieren
APA
Faigner, M., Karayan-Tapon, L., Cortes, U., Ndiaye, B., Martel, M., Rivet, P., Duche, J., Isambert, N., Tougeron, D., & Evrard, C. (2025). Impact of next-generation sequencing on routine clinical practice and patient inclusion in molecularly targeted clinical trials: a retrospective cohort analysis. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-025-04086-7
Vancouver
Faigner M, Karayan-Tapon L, Cortes U, Ndiaye B, Martel M, Rivet P, et al. Impact of next-generation sequencing on routine clinical practice and patient inclusion in molecularly targeted clinical trials: a retrospective cohort analysis. Clinical and Translational Oncology. 2025. doi:10.1007/s12094-025-04086-7
BibTeX
@article{Faigner2025,
author = {Faigner, Mathieu and Karayan-Tapon, Lucie and Cortes, Ulrich and Ndiaye, Birama and Martel, Marine and Rivet, Pierre and Duche, Jade and Isambert, Nicolas and Tougeron, David and Evrard, Camille},
title = {Impact of next-generation sequencing on routine clinical practice and patient inclusion in molecularly targeted clinical trials: a retrospective cohort analysis},
journal = {Clinical and Translational Oncology},
year = {2025},
doi = {10.1007/s12094-025-04086-7}
}
EUVIMED